Clinical Trial Search

Primary: Improvement in Glycemic Control as Assessed by Change in Hemoglobin A1c (HbA1c) — -1.23 HbA1c percentage

Primary: % Participants Downloading Huma App — 95; 0 Participants

Primary: Changes in Beta Cell Function Assessed by Fasting and Stimulated C-peptide Measured at 36 Months. — -0.4; -1.4; 0.1; 0.3 ng per ml

Primary: Number of Participants With Composite Neonatal Morbidity — 149; 163; 62; 55 Participants — p=0.14

Primary: Program Enrollment Rate (%) — 6.1 percentage of invitees

Primary: Program Enrollment Rate (%) — 14 Percentage of participants

Primary: Change From Baseline in HbA1c Levels — -0.12; 0.11 mmol/mol — p=0.0816

Primary: Normalization of Glucose Levels — 9; 2; 4 Participants — p=.035

Primary: Number of Neonates With Composite Adverse Neonatal Outcome — 31; 35 Participants

Primary: Percentage of Time in Target Range (TIR) 3.9-10.0 Millimoles Per Liter (mmol/L) (70-180 Milligrams Per Deciliter (mg/dL) Measured Using CGM (Continuous Glucose…

Primary: Change From Baseline in Total, Basal, and Bolus Exogenous Insulin Requirements — -2.09; 2.83; -1.92; -1.10 mg/dL

Primary: CGM Time Below 54 mg/dL — 0.00; 0.00; 0.00; 0.00 percentage of time

Primary: Type 2 Diabetes Blood Glucose Time in Range (70-180 mg/dL) — 25.31; 19.89; 26.04 percentage of time during CGM use — p=0.1460

Primary: Feasibility of Usage — 168 minutes/week

Primary: Number of Participants Experiencing an Adverse Event (AE) — 6; 6; 0; 4 Participants

Primary: Change in Glucose Levels Between Pre-treatment and End of Treatment as Measured by 24-hour Continuous Glucose Monitoring (CGM) — -4.94; -10.00; -1.21; -11.42 mg/dL…

Primary: Glycemic Control — 109.5; 107.4 mg/dL

Primary: Fasting Plasma Glucose <126 mg/dL and HbA1c < 6.5% at Three Years of Follow-up. — 13; 5; 42; 0 % of patients — p=0.60

Primary: Fasting Insulin — 12.7; 13.1; 16.4; 13.9 μU/mL

Primary: Proportion of Women Who Are Eligible, Screened, Enroll and Remain in the Study — 25; 26 Participants — p=0.9

Primary: Disposition Index — 0.023; 0.149 index

Primary: The Role of Exenatide as Compared to Insulin Monotherapy in Reducing Postprandial Hyperglycemia.

Primary: Beta-cell Function - C-peptide AUC (Area Under the Curve) — 2096; 1725 ng*min/mL

Primary: Change in Mixed-meal-stimulated Peak C-peptide Value (Via Mixed-meal Tolerance Test) After 12 Months of Insulin Pump Therapy, Compared With MDI. — 1.8; 3.1 ng/mL

Primary: The Number of Participants Who Achieved a Hemoglobin A1C <7% — 5; 12 Participants

Primary: Whole-body Glucose Utilization (Rd) — 8.5; 11.0; 12.1 mg/kg FFM/min

Primary: Number of Children With Documented Risk Factors for Type 2 Diabetes — 283; 282 Participants

Primary: % of Excess Weight Loss (EWL) — 37.7 % excess weight loss

Primary: Number of All Consented Participants — 12; 12 Participants

Primary: Change From Baseline in Glycosylated Hemoglobin (HbA1c) at Week 12 — 0.46; 0.18; -0.07; 0.01 Percentage of HbA1c — p=0.061